Fortress Biotech
FBIO
61 hedge funds and large institutions have $6.44M invested in Fortress Biotech in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 9 closing their positions.
0.19% less ownership
Funds ownership: 1.04% → 0.84% (-0.19%)
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
6% less funds holding
Funds holding: 65 → 61 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
53% less capital invested
Capital invested by funds: $13.7M → $6.44M (-$7.27M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SO
STRS Ohio
Columbus,
Ohio
|
+$166K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$100K |
| 3 |
SG Americas Securities
New York
|
+$49.5K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$48.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$48.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$768K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$272K |
| 3 |
Renaissance Technologies
New York
|
-$240K |
| 4 |
JP Morgan Chase
New York
|
-$211K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$181K |
FBIO Hedge Fund Activity: Q4 2018 in Review
61 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q4 2018, worth a combined $6.44M — down 53% from $13.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of FBIO and 5 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 17 added.
The largest buyer was STRS Ohio, adding an estimated $166K. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $768K sold.
- 61 institutional investors held Fortress Biotech (FBIO) as of Q4 2018, down from 65 in Q3 2018.
- Funds reported $6.44M of Fortress Biotech stock for Q4 2018, down 53% quarter-over-quarter.
- 5 funds opened new Fortress Biotech positions in Q4 2018 and 9 closed out, a net change of -4 holders.
- The largest Fortress Biotech buyer in Q4 2018 was STRS Ohio, an estimated $166K added.
- The largest Fortress Biotech seller in Q4 2018 was Granite Point Capital Management, an estimated $768K sold.
Based on aggregated 13F filings for Q4 2018.